TITLE

Voluntary recall of heparin announced

PUB. DATE
April 2008
SOURCE
Hem/Onc Today;4/25/2008, Vol. 9 Issue 7, p22
SOURCE TYPE
Newspaper
DOC. TYPE
Article
ABSTRACT
The article focuses on the voluntary recall of 23 lots of Heparin Sodium USP active pharmaceutical ingredient by Scientific Protein Laboratories LLC as announced by the U.S. Food and Drug Administration in March 2008. A supplier of the company was reportedly informed that one lot of heparin has a heparin-like contaminant and decided to recall the products as a precautionary measure. Customers with the recalled lots being urged to discontinue use and report any adverse reactions are noted.
ACCESSION #
31705852

 

Related Articles

  • Makers of Heparin Seek Help. Stone, Peter H. // National Journal;3/8/2008, Vol. 40 Issue 10, p28 

    The article announces that the nationwide recall of the drug Heparin, which was linked to 19 deaths by the Food and Drug Administration (FDA) has prompted companies that produced the drug to hire K Street help. Baxter International has tapped Mark Brown of King & Spalding while Scientific...

  • Germany Joins U.S. in Recall of Contaminated Heparin. Scott, Alex // Chemical Week;3/17/2008, Vol. 170 Issue 9, p27 

    The article reports on the discovery of potentially lethal contaminated batches of the blood-thinning drug heparin in Germany. Producers have recalled heparin supplies from the German market following severe reactions to batches of the drug by up to 100 patients. U.S. officials have traced the...

  • Heparin Deaths. Kuehn, Bridget M. // JAMA: Journal of the American Medical Association;5/28/2008, Vol. 299 Issue 20, p2379 

    The article discusses several shortcomings in the manufacturing practices of a Chinese producer of an ingredient for heparin that has been linked to several dozen deaths in the U.S. According to the U.S. Food and Drug Administration, Changzhou SPL Company, Ltd. had substandard procedures for...

  • Untitled.  // Biomedical Market Newsletter;12/20/2010, p50 

    The article reports that Braun Medical Inc. was recently notified by its supplier, Scientific Protein Laboratories LLC (SPL), of a nationwide recall of a lot of Heparin Sodium USP Active Pharmaceutical Ingredient (API) sold to B. Braun in the U.S. As stated, the reason was the additional testing...

  • Medtronic withdraws some heparin - coated products.  // Medical Technology & Devices Week;5/12/2008, Vol. 6 Issue 19, p5 

    This article reports on the decision of Medtronic to pull out from the market some of its disposable heart surgery products because of concerns about a coating of contaminated heparin. It called its move an a voluntary and precautionary recall. The Carmeda BioActive surface used during...

  • Baxter recalls remaining lots and doses of heparin sodium vials. Adams, Stacey L. // Infectious Disease News;Mar2008, Vol. 21 Issue 3, p43 

    The article reports on the decision of Baxter Healthcare Corp. to voluntarily recall its remaining batch of heparin sodium injection multi-dose, single-dose vials and HEP-LOCK heparin flush products on February 28, 2008. Due to a lack of suppliers, the U.S. Food and Drug Administration (FDA) did...

  • Heparin-Linked Deaths.  // Critical Care Nurse;Jun2008, Vol. 28 Issue 3, p11 

    The article reports on deaths associated with heparin in the U.S. Baxter Healthcare Corp. recalled all its products from the market with heparin because of reported deaths and adverse reactions linked with the use of heparin. The U.S. Food & Drug Administration (FDA) stated that the...

  • Clexane recalled.  // Australian Nursing Journal;Jun2008, Vol. 15 Issue 11, p7 

    The article reports on the product recall of batches of low molecular weight heparin Clexane or enoxaparin. The drugs have been recalled by the Australian Therapeutic Goods Administration (TGA) due to the detection of an impurity. The U.S. Food and Drug Administration confirmed a clear link...

  • Contaminated Heparin Seized by FDA. Mitka, Mike // JAMA: Journal of the American Medical Association;12/10/2008, Vol. 300 Issue 22, p2597 

    The article reports that on November 6, 2008 the U.S. Food and Drug Administration (FDA) sent federal marshals to Celsus Laboratories Inc. in Cincinnati, Ohio to seize contaminated heparin. The FDA felt that the company did not take sufficient action in recalling the products. On March 6, 2008...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics